Needham & Company Downgrades Neothetics Inc. (NEOT) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Piper Jaffray Downgrades Neothetics Inc. (NEOT) to Neutral
December 15, 2015 6:45 AM ESTPiper Jaffray downgraded Neothetics Inc. (NASDAQ: NEOT) from Overweight to Neutral with a price target of $3.00 (from $20.00) after the company announced that lead product candidate LIPO-202 failed to meet its primary and secondary endpoints in pivotal studies evaluating the product for the localized reduction... More
Neothetics (NEOT) Reports LIPO-202 Phase 3s Missed co-Primary, Secondary Endpoints
December 14, 2015 4:31 PM ESTNeothetics, Inc. (NASDAQ: NEOT) announced top-line results from its AbCONTOUR1 and AbCONTOUR2 U.S.-based pivotal Phase 3 trials to evaluate the safety and efficacy of LIPO-202 for the reduction of central abdominal bulging due to subcutaneous fat. In both studies, LIPO-202 did not meet its co-primary composite and secondary endpoints. The co-primary endpoints were the proportion of subjects who reported an improvement of at least one point on the Patient-Global Abdominal Perception Scale (P-GAPS) and an improvement of at least two points on... More
